Protara Therapeutics (TARA) Reiterated at Overweight by Cantor Fitzgerald After Management Meet

October 15, 2026 7:54 AM

Cantor Fitzgerald analyst Li Watsek reiterated an Overweight rating on Protara Therapeutics (NASDAQ: TARA).The analyst commented, "We hosted Protara management ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found